The Mark Egly Foundation works to find and support promising research relating to breakthroughs for individuals with Alpha1 Antitrypsin Deficiency, all the comorbidities and related conditions, and all the individual situations within Mark’s patent filing that can benefit from Alpha1 Antitrypsin usages!